The generic version is also approved as an adjunctive therapy for partial-onset seizures in patients 17 years of age and older.

“Today’s approval of the first generics for pregabalin, a widely-used medication, is another example of the FDA’s longstanding commitment to advance patient access to lower cost, high-quality generic medicines,” said Janet Woodcock, MD, director of the FDA’s Center for Drug Evaluation and Research.